ProQR Therapeutics (PRQR)
(Delayed Data from NSDQ)
$1.95 USD
+0.12 (6.56%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Brokerage Reports
0 items in cart
ProQR Therapeutics N.V. [PRQR]
Reports for Purchase
Showing records 21 - 40 ( 51 total )
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Positive STELLAR Trial Sets Stage for Registration; Initiation Expected YE21
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Retinal Disease RNA Platform Continues to Advance Across Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Endpoint Perspectives Provide QR-421a With Clinical Context For Advancement
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Inherited Retinal Disease Pipeline Stands to Broadly Deliver in 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
RNA Therapeutics Pipeline Steady as She Goes; Early InSight Extension Study Consistent With Expectations
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Early Look at InSight Extension Study In-line With Expectations
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Progress Anticipated Across Pipeline; Reit Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Progress Anticipated Across Retinal Disease RNA Therapeutics Pipeline in 2020; Reit Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Positive Phase 1/2 Sepofarsen Safety and Topline Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Balanced Clinical Progress Across LCA10, Usher and adRP Programs; Reit Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Believe Now Is an Attractive Entry Point Heading Into Interim Data Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Steady Pipeline Progress With Multiple Catalysts in the Near-Term; Reit Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Our Thoughts Surrounding ProQR''s Opthalmologic Programs Following R-D Day
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Wir Lieben QR-110 Data in Leber''s; Reit Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Corporate Refocus May Begin Yielding Catalysts; Reit Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
ProQR Pivots in 2018 to Focus on Ophthalmology Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A